The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sapronova M.R.

Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia

Shnaĭder N.A.

Krasnoiarskiĭ gosudarstvennvyĭ meditsinskiĭ universitet im. prof. V.F. Voĭno-Iasenetskogo Minzdrava Rossii

Predictors and modifiers of impulse control disorders in Parkinson`s disease

Authors:

Sapronova M.R., Shnaĭder N.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11): 145‑156

DOI: 10.17116/jnevro2016116111145-156

Read: 1625 times

Download PDF (RU)
Contact the author
Table of contents

PREDICTORS AND MODIFIERS OF IMPULSE CONTROL DISORDERS IN PARKINSON`S DISEASE
PREDICTORS AND MODIFIERS OF IMPULSE CONTROL DISORDERS IN PARKINSON`S DISEASE

To cite this article:

Sapronova MR, Shnaĭder NA. Predictors and modifiers of impulse control disorders in Parkinson`s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):145‑156. (In Russ.)
https://doi.org/10.17116/jnevro2016116111145-156

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Clinical presentation and diagnosis of Parkinson’s disease in patients with schi­zophrenia spectrum diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):73-80
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
Chro­nic epidural spinal cord stimulation for gait impairments in Parkinson’s disease and atypical parkinsonism. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):100-112
Evaluation of the effe­ctiveness of the drug Cortexin in combination with the use of the application Apha­sia.No (Afaziyam.Net) in the correction of speech diso­rders in patients with cere­bral infa­rction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):147-151
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Predictors of aortic valve dysfunction after the Ozaki procedure. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):624-628
On mole­cular gene­tic predictors of preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):26-34
Identification of prognostic significant markers of early diagnosis of obesity and meta­bolic diso­rders. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):71-79
Abstract:

Impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior, and eating, are a serious and increasingly recognized psychiatric complication in Parkinson’s disease (PD). ICDs have been most closely related to the use of dopamine agonists (DAs), perhaps more so at higher doses. Possible predictor's for ICDs include male sex, younger age and younger age at PD onset, use of dopaminergic agents. Modifiers of ICDs are pharmacological (medication) and non-pharmacological (surgical, behavioral) treatments.

Keywords:

Parkinson’s disease
impulse control disorder
dopamine dysregulation syndrome
predictors
modifiers
dopamine agonists
dopaminergic drugs
adverse drug events
correction

Authors:

Sapronova M.R.

Voyno-Yasenetsky Krasnoyarsk State Medical University, Krasnoyarsk, Russia

Shnaĭder N.A.

Krasnoiarskiĭ gosudarstvennvyĭ meditsinskiĭ universitet im. prof. V.F. Voĭno-Iasenetskogo Minzdrava Rossii

Close metadata

References:

  1. Sapronova MR, Shnajder NA. Jepidemiologicheskaja i kliniko-geneticheskaja harakteristika bolezni Parkinsona (na primere ZATO Zheleznogorsk Krasnojarskogo kraja). Nevrologija, nejropsihiatrija, psihosomatika. 2014;4:59-64. doi: 10.14412/2074-2711-2014-4-59-64 (In Russ.).
  2. Bastiaens J, Dorfman BJ, Christos PJ, Nirenberg MJ. Prospective cohort study of impulse control disorders in Parkinson’s disease. Movement Disorders. 2013;28(3):327-333. doi: 10.1002/mds.25291
  3. Dagher A, Robbins TW. Personality, addiction, dopamine: insights from Parkinson’s disease. Neuron. 2009;61(4):502-510. doi: 10.1016/j.neuron.2009.01.031
  4. Phu A, Xu Z, Brakoulias V, Mahant N, Fung V, Moore G, Martin A, Starcevic V, Krause M. Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. Journal of Clinical Neuroscience. 2014;21(1):63-66. doi: 10.1016/j.jocn.2013.02.032
  5. Maier F, Merkl J, Ellereit A, Lewis C, Eggers C, Pedrosa D, Kalbe E, Kuhn J, Meyer T, Zurowski M, Timmermann L. Hypomania and mania related to dopamine replacement therapy in Parkinson’s disease. Parkinsonism & Related Disorders. 2014;20(4):421-427. doi: 10.1016/j.parkreldis.2014.01.001
  6. Nikitina AV, Fedorova NV. Impul'sivno-kompul'sivnyj sindrom pri bolezni Parkinsona. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2013;113:7:32-38. (In Russ.).
  7. Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs & Aging. 2013;30(8):587-592. doi: 10.1007/s40266-013-0090-z
  8. O’Sullivan SS, Djamshidian A, Evans AH, Loane CM, Lees AJ, Lawrence AD. Excessive hoarding in Parkinson’s disease. Movement Disorders. 2010;25(8):1026-1033. doi: 10.1002/mds.23016
  9. Weintraub D, Papey K, Siderowf A. Screening for impulse control symptoms in patients with de novo Parkinson disease. Neurology. 2013;80(2):176-180. doi: 10.1212/wnl.0b013e31827b915c
  10. Hodgins DC, Stea JN, Grant, JE. Gambling disorders. The Lancet. 2011;378(9806):1874-1884. doi: 10.1016/s0140-6736(10)62185-x
  11. Koran LM, Faber RJ, Aboujaoude E, Large MD, Serpe RT. Estimated prevalence of compulsive buying behavior in the United States. American Journal of Psychiatry. 2006;163(10):1806-1812. doi: 10.1176/ajp.2006.163.10.1806
  12. Kuzma JM, Black DW. Epidemiology, prevalence, and natural history of compulsive sexual behavior. Psychiatric Clinics of North America. 2008;31(4):603-611. doi: 10.1016/j.psc.2008.06.005
  13. Smink FR, van Hoeken D, Hoek HW. Epidemiology, course, and outcome of eating disorders. Current Opinion in Psychiatry. 2013;26(6):543-548. doi: 10.1097/yco.0b013e328365a24f
  14. Giladi N, Weitzman N, Schreiber S Shabtai H, Peretz C. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonist treatment and age at motor symptoms onset. Journal of Psychopharmacology. 2006;21(5):501-506. doi: 10.1177/0269881106073109
  15. Perez-Lloret S, Rey M, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc J-L, Rascol O. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease Clinical Neuropharmacology. 2012;35(6): 261-265. doi: 10.1097/wnf.0b013e31826e6e6d
  16. Willis A, Schootman M, Kung N, Racette A. Epidemiology and neuropsychiatric manifestations of young onset Parkinson’s disease in the United States. Parkinsonism & Related Disorders. 2013;19(2):202-206. doi: 10.1016/j.parkreldis.2012.09.014
  17. Chazeron I, Llorca PM, Chereau-Boudet I, Blanc O, Perriot J, Ouchchane L, Ulla M, Debilly B, Derost P, Durif F. Hypersexuality and pathological gambling in Parkinson’s disease: a cross-sectional case-control study. Movement Disorders. 2011;26(11):2127-2130. doi: 10.1002/mds.23845
  18. Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, Caporali A, Mancini F, Pezzoli G, Ceravolo R, Bonuccelli U, Barone P. Impulsivity and compulsivity in drug-naive patients with Parkinson’s disease. Movement Disorders. 2011;26(3):464-468. doi: 10.1002/mds.23501
  19. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology. 2010;67(5):589-595. doi: 10.1001/archneurol.2010.65
  20. Hassan A, Bower JH, Kumar N, Matsumoto JY, Fealey RD, Josephs KA, Ahlskog JE. Dopamine agonist-triggered pathologicla behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism & Related Disorders. 2011;17(4):260-264. doi: 10.1016/j.parkreldis.2011.01.009
  21. Lim SY, Tan ZK, Ngam PI, Lor TL, Mohamed H, Schee JP, Tan AK, Goh JY, Ooi E, Soh PC. Impulsive-compulsive behaviors are common in Asian Parkinson’s disease patients: assessment using the QUIP. Parkinsonism & Related Disorders. 2011;17(10):761-764. doi: 10.1016/j.parkreldis.2011.07.009
  22. Chiang H-L, Huang Y-S, Chen S-T, Y-R Wu. Are there ethnic differences inimpulsive/compulsive behaviors in Parkinson’s disease? European Journal of Neurology. 2011;19(3):494-500. doi: 10.1111/j.1468-1331.2011.03571.x
  23. Callesen MB, Weintraub D, Damholdt MF, Møller A. Impulsive and compulsive behaviors among Danish patients with Parkinson’s disease:prevalence, depression, and personality. Parkinsonism & Related Disorders. 2014;20(1):22-26. doi: 10.1016/j.parkreldis.2013.09.006
  24. Sarathchandran P, Soman S, Sarma G, Krishnan S, Kishore A. Impulse control disoder and related behaviors in Indian patients with Parkinson’s disease. Movement Disorders. 2013;28(13):1901-1902. doi: 10.1002/mds.25557
  25. Rodrıguez-Violante M, Gonzalez-Latapi P, Cervantes-Arriaga A, Camacho-Ordonez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson’s disease patients. Parkinsonism & Related Disorders.2014;20(8):907-910. doi: 10.1016/j.parkreldis.2014.05.014
  26. Miyasaki J, Hassan KL, Lang AE, Voon V. Punding prevalence in Parkinson’s disease. Movement Disorders. 2007;22(8):1179-1181. doi: 10.1002/mds.21296
  27. Najem D. Psihologija i psihiatrija v SShA. Per. Dubrovinoj LV, Vojskunskoj PI. M.: Progress; 1984.
  28. Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Amantadine use associated with impulse control disorders in Parkinson disease in crosssectional study. Annals of Neurology. 2010;68(6):963-968. doi: 10.1002/ana.22164
  29. Garcia-Ruiz P, Castrillo J, Alonso-Canovas A, Barcenas AH, Vela L, Alonso PS, Mata M, Gonzalez NO, Fernandez IM. Impulse control disorders in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. Journal of Neurology, Neurosurgery & Psychiatry. 2014;85(8):840-844. doi: 10.1136/jnnp-2013-306787
  30. Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I. [11C]-(1)-PHNO PET imaging of dopamine D2/3receptors in Parkinson’s disease with impulse control disorders. Movement Disorders. 2015; 30(2):160-166. doi: 10.1002/mds.26135
  31. Poletti M, Logi C, Lucetti C, Dotto P, Baldacci F, Vergallo A, Ulivi M, Sarto S, Rossi G, Ceravolo R, Bonuccelli U. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson’s disease: association with dopaminergic drugs. Journal of Clinical Psychopharmacology. 2013;33(5):691-694. doi: 10.1097/jcp.0b013e3182979830
  32. Slutske WS. Common genetic vulnerability for pathological gambling and alcohol dependence in men. Archives of General Psychiatry. 2000;57(7):666-673. doi: 10.1001/archpsyc.57.7.666
  33. Cormier F, Mueliner J, Corvol J-C. Genetics of impusle control disorders in Parkinson’s disease. Journal of Neural Transmission. 2012;120(4):665-671. doi: 10.1007/s00702-012-0934-4
  34. Lee JY, Lee EK, Park SS, Lim J-Y, Kim HJ, Kim JS, Jeon BS. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson’s disease. Movement Disorders. 2009;24(12):1803-1810. doi: 10.1002/mds.22678
  35. Lee JY, Jeon BS, Kim HJ, Park SS. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson’s disease. Parkinsonism & Related Disorders. 2012;18(1):76-78. doi: 10.1016/j.parkreldis.2011.08.009
  36. Vallelunga A, Flaibani R, Formento-Dojot P, Biundo R, Facchini S, Antonini A. Role of genetic polymorphisms of the dopaminergic system in Parkinson’s disease patients with impulse control disorders. Parkinsonism & Related Disorders. 2012;18(4):397-399. doi: 10.1016/j.parkreldis.2011.10.019
  37. Buckholtz JW, Treadway MT, Cowan RL, Woodward ND, Li R, Ansari MS, Baldwin RM, Schwartzman AN, Shelby ES, Smith CE, Kessler RM, Zald DH. Dopaminergic network differences in human impulsivity. Science. 2010;329(5991):532. doi: 10.1126/science.1185778
  38. Cilia R, Ko JH, Cho SS, Eimeren T, Marotta G, Pellecchia G, Pezzoli G, Antonini A, Strafella AP. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiology of Disease. 2010;39(1):98-104. doi: 10.1016/j.nbd.2010.03.013
  39. Ray N, Miyasaki JM, Zurowski M, Ko JH, Cho SS, Pellecchia G, Antonelli F, Houle S, Lang AE, Strafella AP. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. Neurobiology of Disease. 2012;48(3):519-525. doi: 10.1016/j.nbd.2012.06.021
  40. Ballanger B, van Eimeren T, Moro E, Lozano AM, Hamani C, Boulinguez P, Pellecchia G, Houle S, Poon YY, Lang AE, Strafella AP. Stimulation of the subthalamic nucleus and impulsivity: release your horses. Annals of Neurology. 2009;66(6):817-824. doi: 10.1002/ana.21795
  41. Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, Dolan RJ, Hallett M. Dopamine agonists and risk:impulse control disorders in Parkinson’s disease. Brain. 2011;134(5):1438-1446. doi: 10.1093/brain/awr080
  42. Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, Weintraub D. Decreased ventral striatal activity with impulse control disorders in Parkinson’s disease. Movement Disorder. 2010;25(11):1660-1669. doi: 10.1002/mds.23147
  43. Djamshidian A, Jha A, O’Sullivan SS, Silveira-Moriyama L, Jacobson C, Brown P, Lees A, Averbeck BB. Risk and learning in impulsive and nonimpulsive patients with Parkinson’s disease. Movement Disorders. 2010;25(13):2203-2210. doi: 10.1002/mds.23247
  44. Bari A, Mar AC, Theobald DE, Elands SA, Oganya KCNA, Eagle DM, Robbins TW. Prefrontal and monoaminergic contributions to stop-signal task performance in rats. Journal of Neuroscience. 2011;31(25):9254-9263. doi: 10.1523/jneurosci.1543-11.2011
  45. Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Selective serotonin reuptake inhibition modulates response inhibition in Parkinson’s disease. Brain. 2014;137(4):1145-1155. doi: 10.1093/brain/awu032
  46. Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, Shetler ND, Brown AK, Monterosso JR, Aron AR, Mandelkern MA, Poldrack RA, London ED. Striatal dopamine D(2)/D(3) receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. Journal of Neuroscience. 2012;32(21):7316-7324. doi: 10.1523/jneurosci.4284-11.2012
  47. Li CS, Yan P, Sinha R, Lee TW. Subcortical processes of motor response inhibition during a stop signal task. Neuroimage. 2008;41(4):1352-1363. doi: 10.1016/j.neuroimage.2008.04.023
  48. Roitman JD, Loriaux AL. Nucleus accumbens responses differentiate execution and restraint in reward-directed behavior. Journal of Neurophysiology. 2013;111(2):350-360. doi: 10.1152/jn.00350.2013
  49. Cui G, Jun SB, Jin X, Pham MD, Vogel SS, Lovinger DM, Costa RM. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature. 2013;494(7436):238-242. doi: 10.1038/nature11846
  50. Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology. 2010;35(1):27-47. doi: 10.1038/npp.2009.93
  51. Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clinical Neuropharmacology. 2010;33(1):5-10. doi: 10.1097/wnf.0b013e3181b7926f
  52. Vitale C, Santangelo G, Erro R, Errico D, Manganelli F, Improta I, Moccia M, Barone P. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson’s disease: report of 2 cases. Parkinsonism & Related Disorders. 2013;19(4):483-484. doi: 10.1016/j.parkreldis.2012.11.008
  53. Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. The British Journal of Psychiatry. 2011;199(2):158-159. doi: 10.1192/bjp.bp.110.084996
  54. Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medicationrelated pathological gambling in Parkinson disease. Movement Disorders. 2010;25(12):1994-1995. doi: 10.1002/mds.23177
  55. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Eimeren TV, Rusjan P, Houle S, Strafella AP. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132(5):1376-1385. doi: 10.1093/brain/awp054
  56. Schreglmann SR, Gantenbein AR, Eisele G, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.Parkinsonism & Related Disorders. 2012;18(2):207-209. doi: 10.1016/j.parkreldis.2011.10.010
  57. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Movement Disorders. 2014;30(4):510-516. doi: 10.1002/mds.26067
  58. Antonini A. Continuous dopaminergic stimulation: from theory to linical practice.Parkinsonism & Related Disorders. 2007;13:24-28. doi: 10.1016/j.parkreldis.2007.06.002
  59. Catalan MJ, de Pablo-Fernandez E, Villanueva C, Fernández-Diez S, Lapeña-Montero T, García-Ramos R, López-Valdés E. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson’s disease. Movement Disorders. 2013;28(14):2007-2010. doi: 10.1002/mds.25636
  60. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, anagunasAV, Othman AA, Widnell KL, Robieson WZ, Pritchett Y, Chatamra K, Benesh J, Lenz RA, Antonini A. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, doubleblind, double-dummy study. The Lancet Neurology. 2014;13(2):141-149. doi: 10.1016/s1474-4422(13)70293-x
  61. Okun MS, Weintraub D. Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brainstimulation and intestinal levodopa? Movement Disorders. 2013;28(14):1915-1919. doi: 10.1002/mds.25735
  62. Mandat TS, Hurwitz T, Honey CR. Hypomania as an adverse effect of subthalamic nucleus stimulation: report of two cases. Acta Neurochirurgica. 2006;148(8):895-898. doi: 10.1007/s00701-006-0795-4
  63. Rodriguez-Oroz MC, Lopez-Azcarate J, Garcia-Garcia D, Alegre M, Toledo J, Valencia M, Guridi J, Artieda J, Obeso JA. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson’s disease. Brain. 2010;134(1):36-49. doi: 10.1093/brain/awq301
  64. Eusebio A, Witjas T, Cohen J, Fluchere F, Jouve E, Regis J, Azulay J-P. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2013;84(8):868-874. doi: 10.1136/jnnp-2012-302387
  65. Thobois S, Ardouin C, Lhommee E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, Bars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: predictors and underlying mesolimbic denervation. Brain. 2010;133(4):1111-1127. doi: 10.1093/brain/awq032
  66. Zahodne LB, Susatia F, Bowers D, Ong TL, Jacobson CE, Okun MS, Rodriguez RL, Malaty IA, Foote KD, Fernandez HH. Binge eating in Parkinson’s disease: prevalence, correlates and the contribution of deep brain stimulation. Journal of Neuropsychiatry. 2011;23(1):56-62. doi: 10.1176/appi.neuropsych.23.1.56
  67. Agari T, Date I. Stimulation of subthalamic nucleus for Parkinson’s disease. Deep Brain Stimulation for Neurological Disorders.2014;73-86. doi: 10.1007/978-3-319-08476-3_7
  68. Moum SJ, Price CC, Limotai N, Oyama G, Ward H, Jacobson C, Foote KD, Okun MS. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One. 2012;7(1):29768. doi: 10.1371/journal.pone.0029768
  69. Lim SY, O’Sullivan SS, Kotschet K, Gallagher DA, Lacey C, Lawrence AD, Lees AJ, O’Sullivan DJ, Peppard RF, Rodrigues JP, Schrag A, Silberstein P, Tisch S, Evans AH. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson’s disease.Journal of Clinical Neuroscience. 2009;16(9):1148-1152. doi: 10.1016/j.jocn.2008.12.010
  70. Jimenez-Murcia S, Bove FI, Israel M, Steiger H, Fernández-Aranda F, Álvarez-Moya E, Granero R, Penelo E, Vergé B, Aymamí M-N, Santamaría JJ, Gómez-Peña M, Moragas L, Savvidou LG, Menchón JM. Cognitive-behavioral therapy for pathological gambling in Parkinson’s disease: a pilot controlled study. European Addiction Research. 2012;18(6):265-274. doi: 10.1159/000337442
  71. Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, Mack J, Brown RG, David AS. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80:792-799. doi: 10.1212/wnl.0b013e3182840678
  72. Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. American Journal of Psychiatry. 2011;168(10):1066-1074. doi: 10.1176/appi.ajp.2011.10111669
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.